Agree Realty Corporation logo

Agree Realty Corporation (ADC)

Market Closed
11 Jun, 20:00
NYSE NYSE
$
74. 54
-0.19
-0.25%
$
8.22B Market Cap
- P/E Ratio
1.01% Div Yield
784,644 Volume
- Eps
$ 74.73
Previous Close
Day Range
74.12 75.19
Year Range
59.66 79.65
Earnings results expected in 39 days
Want to track ADC and more in your Portfolio? šŸŽÆ
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Compound Your Retirement With These 5 Monthly Dividend REITs

Compound Your Retirement With These 5 Monthly Dividend REITs

I focus on the power of compounding—both in life and investing—and recommend a slow, steady approach to building wealth. My top five monthly dividend REIT picks are Realty Income, LTC Properties, Agree Realty, Healthpeak, and Apple Hospitality, all offering value and safety. Each REIT is attractively valued, boasts strong balance sheets, and provides well-covered, above-average yields, supporting a SWAN (sleep well at night) retirement.

Seekingalpha | 14 hours ago
Agree Realty: Add The King Of Retail REITs To Your Portfolio

Agree Realty: Add The King Of Retail REITs To Your Portfolio

Agree Realty Corporation is a net lease real estate investment trust, with a top tier retailer tenant list. ADC consistently outperforms the real estate sector indexes, paying a consistent monthly dividend. Q1 2025 results were strong: double-digit AFFO growth, dividend increase, and raised guidance, reflecting momentum from a robust U.S. economy.

Seekingalpha | 1 day ago
Agree Realty Declares Monthly Common and Preferred Dividends

Agree Realty Declares Monthly Common and Preferred Dividends

ROYAL OAK, Mich. , June 10, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.256 per common share.

Prnewswire | 1 day ago
Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology

Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology

Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug delivery technologies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its U.S. patent application covering one of its next-generation antibody-drug conjugate (ADC) technologies. The allowance of U.S. patent application no.

Newsfilecorp | 2 days ago
ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI343 (Novel Anti-CLDN18.2 ADC) From the Phase 1 Clinical Study in Patients with Advanced Pancreatic Cancer

ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI343 (Novel Anti-CLDN18.2 ADC) From the Phase 1 Clinical Study in Patients with Advanced Pancreatic Cancer

SAN FRANCISCO and SUZHOU, China , June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, updated the Phase 1 study results of IBI343, a novel anti-CLDN18.2 ADC, for the treatment of advanced pancreatic cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. With extended follow-up and more mature data on progression-free survival (PFS) and overall survival (OS), IBI343 has demonstrated promising therapeutic efficacy in patients with CLDN18.2-positive advanced pancreatic cancer.

Prnewswire | 1 week ago
2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors

2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors

SAN FRANCISCO and SUZHOU, China , June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, updated the clinical data of IBI354 (HER2 monoclonal antibody-camptothecin derivative conjugate) in advanced solid tumors at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. IBI354 has demonstrated promising anti-tumor efficacy and favorable safety profiles across multiple solid tumors.

Prnewswire | 1 week ago
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

LAUSANNE, Switzerland , June 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 107,550 of the Company's common shares to two new employees on June 2, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.

Prnewswire | 1 week ago
5 Monthly Dividend REITs To Retire With Passive Income

5 Monthly Dividend REITs To Retire With Passive Income

Many REITs pay dividends on a monthly basis. Some of them are offering high dividend yields today. I present 5 of the best monthly paying REITs for passive income.

Seekingalpha | 1 week ago
Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

INDIANAPOLIS , June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) demonstrated an encouraging safety profile and anti-tumor activity across dose and FRα expression levels in women with heavily pre-treated platinum-resistant ovarian cancer, including patients previously treated with mirvetuximab soravtansine. A preliminary overall objective response rate (ORR) of 55% was observed at the potential recommended Phase 2 dose of 4 mg/kg.

Prnewswire | 1 week ago
Lesson Learned: Stay Inside Your Circle Of Competence

Lesson Learned: Stay Inside Your Circle Of Competence

I maintain a heavy allocation to REITs, leveraging my lifelong real estate expertise and focusing on my circle of competence for superior risk-adjusted returns. Agree Realty stands out for its high-quality tenant base, disciplined management, and predictable dividend growth, making it a core long-term holding. Digital Realty benefits from global data center demand, scale, and prudent balance sheet management, supporting robust growth and a well-covered dividend.

Seekingalpha | 1 week ago
Nothing But Net (Lease REITs)

Nothing But Net (Lease REITs)

Net Lease REITs create value by investing at returns above their cost of capital; WACC is a key metric for quality assessment. Top Net Lease REITs like Agree Realty, Essential Properties, Four Corners, VICI, and Realty Income have the most attractive WACCs and investment spreads. High-yield or cheap REITs often have elevated payout ratios and weaker balance sheets, signaling higher risk and possible dividend instability.

Seekingalpha | 1 week ago
Bad News For The Market, Good News For Income Investors

Bad News For The Market, Good News For Income Investors

The market has become an uncertain place. Neither equities nor bonds offer safety. Such times create opportunities.

Seekingalpha | 2 weeks ago
Loading...
Load More